Andrew Fesnak
Program Director, MRA · University of Pennsylvania Health System
Credentials: · · · · ·
History
Present- Present
- 2016–2019
- 2007–2011
Research
CRISPR-engineered T cells in patients with refractory cancer
Science · 2020 · 1,187 citations
Engineered T cells: the promise and challenges of cancer immunotherapy
Review · Nature reviews. Cancer · 2016 · First of 3 authors · 832 citations
Scalable Manufacturing of CAR T cells for Cancer Immunotherapy
Review · Blood Cancer Discovery · 2021 · 252 citations
5 papers
3 papers
2 papers
2 papers
2 papers
- TS
2 papers
1 paper
- AB
1 paper
